Skip to main content

Compare Stocks

Date Range: 

 Shattuck LabsIndiviorAntibe TherapeuticsAntibe TherapeuticsRepare Therapeutics
SymbolNASDAQ:STTKOTCMKTS:INVVYNASDAQ:ATBPDOTCMKTS:ATBPDNASDAQ:RPTX
Price Information
Current Price$26.79$10.31$3.28$3.38$32.38
52 Week RangeBuyBuyN/AN/ABuy
MarketRank™
Overall Score1.50.80.10.11.6
Analysis Score3.50.00.00.02.5
Community Score3.51.90.00.03.9
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.00.00.8
Earnings & Valuation Score0.61.90.60.60.6
Analyst Ratings
Consensus RecommendationBuyBuyN/AN/ABuy
Consensus Price Target$45.60N/AN/AN/A$40.20
% Upside from Price Target70.21% upsideN/AN/AN/A24.15% upside
Trade Information
Market Cap$1.12 billion$1.51 billion$1.27 billion$1.31 billion$1.20 billion
BetaN/A0.30.570.57N/A
Average Volume145,5578,31029,71029,710140,263
Sales & Book Value
Annual RevenueN/A$785 million$7.51 million$7.51 millionN/A
Price / SalesN/A1.93169.02174.18N/A
CashflowN/A$2.06 per shareN/AN/AN/A
Price / CashN/A5.01N/AN/AN/A
Book ValueN/A$1.43 per share$0.10 per share$0.10 per shareN/A
Price / BookN/A7.2132.8033.80N/A
Profitability
Net IncomeN/A$134 million$-14,540,000.00$-14,540,000.00N/A
EPSN/A$1.15($0.50)($0.50)N/A
Trailing P/E Ratio0.00N/AN/AN/A0.00
Forward P/E RatioN/A17.47N/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A-31.93%-273.96%-273.96%N/A
Return on Equity (ROE)N/A-4.15%-176.23%-150.49%N/A
Return on Assets (ROA)N/A-0.26%-106.91%-98.51%N/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A2.89%N/AN/AN/A
Current Ratio8.63%1.82%6.55%5.97%35.44%
Quick Ratio8.63%1.69%5.95%5.42%35.44%
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/A64.81%
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
Employees597884747102
Shares Outstanding41.91 million146.92 million387.00 million387.00 million36.98 million
Next Earnings Date8/9/2021 (Estimated)N/AN/AN/A8/12/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Repare Therapeutics (NASDAQ:RPTX) Releases  Earnings Results, Misses Estimates By $0.07 EPSRepare Therapeutics (NASDAQ:RPTX) Releases Earnings Results, Misses Estimates By $0.07 EPS
americanbankingnews.com - May 14 at 11:50 AM
Repare Therapeutics Provides Business Update and Reports First Quarter 2021 Financial ResultsRepare Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results
wallstreet-online.de - May 14 at 1:54 AM
Repare Therapeutics (NASDAQ:RPTX) Sees Large Volume IncreaseRepare Therapeutics (NASDAQ:RPTX) Sees Large Volume Increase
americanbankingnews.com - May 12 at 11:50 AM
Heres Why Were Not At All Concerned With Repare Therapeutics (NASDAQ:RPTX) Cash Burn SituationHere's Why We're Not At All Concerned With Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Situation
finance.yahoo.com - May 11 at 1:28 PM
Repare Therapeutics (NASDAQ:RPTX) Shares Gap Down to $33.04Repare Therapeutics (NASDAQ:RPTX) Shares Gap Down to $33.04
americanbankingnews.com - May 7 at 11:52 AM
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306, a First-in-Class, Selective, Oral Inhibitor of PKMYT1Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306, a First-in-Class, Selective, Oral Inhibitor of PKMYT1
finance.yahoo.com - May 3 at 7:44 AM
Zacks: Brokerages Anticipate Repare Therapeutics Inc. (NASDAQ:RPTX) Will Announce Earnings of -$0.49 Per ShareZacks: Brokerages Anticipate Repare Therapeutics Inc. (NASDAQ:RPTX) Will Announce Earnings of -$0.49 Per Share
americanbankingnews.com - May 2 at 6:16 PM
Repare Therapeutics (NASDAQ:RPTX) Shares Gap Down to $33.10Repare Therapeutics (NASDAQ:RPTX) Shares Gap Down to $33.10
americanbankingnews.com - April 29 at 3:36 PM
Morgan Stanley Raises Repare Therapeutics (NASDAQ:RPTX) Price Target to $45.00Morgan Stanley Raises Repare Therapeutics (NASDAQ:RPTX) Price Target to $45.00
americanbankingnews.com - April 26 at 10:58 AM
Morgan Stanley Increases Repare Therapeutics (NASDAQ:RPTX) Price Target to $45.00Morgan Stanley Increases Repare Therapeutics (NASDAQ:RPTX) Price Target to $45.00
marketbeat.com - April 26 at 9:21 AM
Repare Therapeutics (NASDAQ:RPTX) Stock Price Down 2.5%Repare Therapeutics (NASDAQ:RPTX) Stock Price Down 2.5%
americanbankingnews.com - April 21 at 2:02 PM
Repare Therapeutics to Present at the 2021 Bloom Burton & Co. Virtual Healthcare Investor ConferenceRepare Therapeutics to Present at the 2021 Bloom Burton & Co. Virtual Healthcare Investor Conference
finance.yahoo.com - April 13 at 9:07 AM
Repare Therapeutics to Highlight Program Progress for RP-6306 at Today’s Virtual Investor Day EventRepare Therapeutics to Highlight Program Progress for RP-6306 at Today’s Virtual Investor Day Event
finance.yahoo.com - April 8 at 1:08 PM
Valence Discovery to Support Repare Therapeutics on AI-Enabled Drug Discovery in Precision OncologyValence Discovery to Support Repare Therapeutics on AI-Enabled Drug Discovery in Precision Oncology
finance.yahoo.com - March 18 at 12:36 PM
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial ResultsRepare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - March 4 at 8:18 PM
Repare Therapeutics Announces March 2021 Virtual Investor Conference ParticipationRepare Therapeutics Announces March 2021 Virtual Investor Conference Participation
finance.yahoo.com - February 23 at 12:00 PM
Could The Repare Therapeutics Inc. (NASDAQ:RPTX) Ownership Structure Tell Us Something Useful?Could The Repare Therapeutics Inc. (NASDAQ:RPTX) Ownership Structure Tell Us Something Useful?
finance.yahoo.com - February 9 at 5:07 PM
Repare Therapeutics to Present at Virtual Investor Conferences in JanuaryRepare Therapeutics to Present at Virtual Investor Conferences in January
finance.yahoo.com - January 4 at 9:38 AM
Hedge Fund and Insider Trading News: Paul Marshall, Larry Robbins, Alden Global Capital, Square Inc (SQ), Repare Therapeutics Inc (RPTX), and MoreHedge Fund and Insider Trading News: Paul Marshall, Larry Robbins, Alden Global Capital, Square Inc (SQ), Repare Therapeutics Inc (RPTX), and More
insidermonkey.com - December 31 at 7:32 PM
Repare Therapeutics Insiders Establish Automatic Securities Disposition PlansRepare Therapeutics Insiders Establish Automatic Securities Disposition Plans
finance.yahoo.com - December 31 at 7:32 PM
Repare Therapeutics Inc. (RPTX)Repare Therapeutics Inc. (RPTX)
realmoney.thestreet.com - December 30 at 11:30 PM
Repare Therapeutics: CRISPR-Enabled Technology Might Unlock New TherapiesRepare Therapeutics: CRISPR-Enabled Technology Might Unlock New Therapies
seekingalpha.com - December 30 at 6:30 PM
What Canada needs to do to build a world-class biotech sectorWhat Canada needs to do to build a world-class biotech sector
theglobeandmail.com - December 23 at 10:57 PM
Repare Therapeutics Inc Registered Shs OverweightRepare Therapeutics Inc Registered Shs Overweight
markets.businessinsider.com - December 17 at 11:09 PM
Repare Therapeutics Added to the NASDAQ Biotechnology IndexRepare Therapeutics Added to the NASDAQ Biotechnology Index
finance.yahoo.com - December 17 at 6:08 PM
Is RPTX A Good Stock To Buy Now?Is RPTX A Good Stock To Buy Now?
finance.yahoo.com - December 15 at 11:57 PM
DateCompanyBrokerageAction
4/20/2021Shattuck LabsBerenberg BankInitiated Coverage
1/20/2021Shattuck LabsCitigroupBoost Price Target
1/11/2021Shattuck LabsEvercore ISIInitiated Coverage
11/3/2020Shattuck LabsSmith Barney CitigroupInitiated Coverage
11/3/2020Shattuck LabsCowenInitiated Coverage
11/3/2020Shattuck LabsNeedham & Company LLCInitiated Coverage
11/3/2020Shattuck LabsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated Coverage
7/27/2020IndiviorJefferies Financial GroupUpgrade
7/27/2020IndiviorStifel NicolausUpgrade
4/26/2021Repare TherapeuticsMorgan StanleyBoost Price Target
12/29/2020Repare TherapeuticsNorthland SecuritiesReiterated Rating
9/17/2020Repare TherapeuticsBloom BurtonReiterated Rating
7/14/2020Repare TherapeuticsThe Goldman Sachs GroupInitiated Coverage
7/14/2020Repare TherapeuticsPiper SandlerInitiated Coverage
(Data available from 5/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.